慢性乙型肝炎核苷(酸)类似物治疗应答的性别差异:一项多中心纵向研究
该回顾性队列研究纳入3388例初治成人慢性乙型肝炎患者(女性1250例,男性2138例),来自22个中心的真实世界数据,比较恩替卡韦或替诺福韦治疗后的病毒学应答、生化应答、完全应答及肝细胞癌发生率。经倾向性评分匹配后,女性与男性5年累积病毒学应答率(91.3% vs 90.3%)和肝细胞癌发生率(5.1% vs 4.4%)相似,但女性生化应答率(84.0% vs 90.9%)和完全应答率(78.8% vs 83.4%)较低;男性获得生化应答(SHR 1.31)和完全应答(SHR 1.16)的可能性更高。
要点
- 匹配后女性与男性5年累积病毒学应答率相似(91.3% vs 90.3%,P=.40)。
- 匹配后女性生化应答率低于男性(84.0% vs 90.9%,P<.001)。
- 匹配后男性生化应答(SHR 1.31)和完全应答(SHR 1.16)可能性更高。
核心结论
- 慢性乙型肝炎患者核苷(酸)类似物治疗结局存在性别差异,男性临床缓解可能性较女性高16%,生化应答可能性较女性高31%,而病毒学应答和肝细胞癌发生率两组相似。
研究设计与样本
- 回顾性队列研究,纳入来自22个中心(阿根廷、韩国、日本、台湾、美国)的3388例初治成人慢性乙型肝炎患者,女性1250例、男性2138例,启动恩替卡韦或替诺福韦治疗。
- 采用倾向性评分匹配平衡男女组背景特征,采用竞争风险分析估计病毒学应答、生化应答、完全应答和肝细胞癌的发生率及亚分布风险比(SHR)。
主要发现
- 女性较男性年龄更大(52.0 vs 48.6岁),超重/肥胖比例更低(49.3% vs 65.7%),糖尿病比例更低(9.9% vs 13.1%),肝硬化比例更低(27.9% vs 33.0%),HBV DNA水平更低(5.9 vs 6.0 log10 IU/mL),丙氨酸氨基转移酶水平更低(91 vs 102 IU/L)(均P<.01)。
- 倾向性评分匹配后,女性与男性5年累积病毒学应答率相似(91.3% vs 90.3%,P=.40),肝细胞癌发生率相似(5.1% vs 4.4%,P=.64)。
- 匹配后女性生化应答率低于男性(84.0% vs 90.9%,P<.001),完全应答率低于男性(78.8% vs 83.4%,P=.016)。
- 男性获得生化应答的可能性高于女性(SHR 1.31,95%CI 1.17-1.46,P<.001),获得完全应答的可能性高于女性(SHR 1.16,95%CI 1.03-1.31,P=.016),病毒学应答和肝细胞癌风险两组相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is unclear if there may be sex differences in response to nucleos(t)ide analogs including virologic response (VR), biochemical response (BR), complete response (CR), and hepatocellular carcinoma (HCC) incidence among hepatitis B patients. We compared nucleos(t)ide analog treatment outcomes by sex. METHODS: We performed a retrospective cohort study of 3388 treatment-naïve adult hepatitis B patients (1250 female, 2138 male) from the Real-World Evidence from the Global Alliance for the Study of Hepatitis B Virus consortium who initiated therapy with either entecavir or tenofovir from 22 sites (Argentina, Korea, Japan, Taiwan, and the United States). We used propensity-score matching to balance background characteristics of the male and female groups and competing-risks analysis to estimate the incidence and subdistribution hazard ratios (SHRs) of VR, BR, CR, and HCC. RESULTS: Females (vs males) were older (52.0 vs 48.6 y); less likely to be overweight/obese (49.3% vs 65.7%), diabetic (9.9% vs 13.1%), or cirrhotic (27.9% vs 33.0%); and had a lower HBV DNA level (5.9 vs 6.0 log10 IU/mL) and alanine aminotransferase level (91 vs 102 IU/L) (all P < .01). However, after propensity-score matching, relevant background characteristics were balanced between the 2 groups. Females (vs males) had similar 5-year cumulative VR (91.3% vs 90.3%; P = .40) and HCC incidence rates (5.1% vs 4.4%; P = .64), but lower BR (84.0% vs 90.9%; P < .001) and CR (78.8% vs 83.4%; P = .016). Males were more likely to achieve BR (SHR, 1.31; 95% CI, 1.17-1.46; P < .001) and CR (SHR, 1.16; 95% CI, 1.03-1.31; P = .016), but VR and HCC risks were similar. CONCLUSIONS: Sex differences exist for treatment outcomes among hepatitis B patients. Male sex was associated with a 16% higher likelihood of clinical remission and a 31% higher likelihood of biochemical response than females, while virologic response and HCC incidence were similar between the 2 groups.
引用
- Chau A, Yeh ML, Tsai PC, et al. Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study. Clin Gastroenterol Hepatol. 2023. PMID: 37734582. doi:10.1016/j.cgh.2023.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。